Avelo’s First Peer-Reviewed Publication Highlights Breath Sampling Potential for Tuberculosis Diagnosis

August 22, 2025. Avelo’s first peer-reviewed publication has been released in the Journal of Clinical Microbiology, presenting the results of a proof-of-principle study evaluating AveloMask as a novel breath aerosol collection kit for airborne Mycobacterium tuberculosis (Mtb).

🔗 Access the publication here

This publication marks a significant milestone for Avelo and reflects the dedication of a global team of researchers and clinicians working toward simpler, more accessible diagnostic solutions for infectious diseases. The study demonstrates that breath sampling with AveloMask is feasible and has the potential to detect airborne M. tuberculosis in patients with pulmonary TB.

Avelo would like to thank its team and all collaborators across two continents for their hard work and contributions: Zandile Booi, Jamie van Schalkwyk, Theresa Heinrich, Stefan M. Botha, Peter Sander, Adithya Cattamanchi, Stephan Hubold, Claudia M. Denkinger, Grant Theron, Christina Fialová, Christian Adlhart, and Rouxjeane Venter.

This early-stage work underscores the potential of breath-based diagnostics and supports Avelo’s mission to bring fast, non-invasive diagnostic sampling closer to the patient.

About Avelo

Avelo AG, the Swiss breath sampling company, aims to revolutionize the diagnosis of tuberculosis and lower respiratory tract infections causing pneumonia. Its breath collection device enables non-invasive collection of pathogens from breath aerosols and works with existing PCR tests. The novel device is designed for broad utility, similar to other sample collection technologies such as blood tubes. Founded in 2020, Avelo has a talented team experienced in business development, functional materials, product development, clinical research, molecular diagnostics, quality and regulatory, and is based in Zurich-Schlieren.